Vita 34 AG
XETRA:V3V
Relative Value
The Relative Value of one V3V stock under the Base Case scenario is 6.94 EUR. Compared to the current market price of 5.15 EUR, Vita 34 AG is Undervalued by 26%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
V3V Competitors Multiples
Vita 34 AG Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
DE |
Vita 34 AG
XETRA:V3V
|
81.5m EUR | 1.1 | -3.3 | -6.1 | -3.8 | ||
US |
C
|
Cigna Group
XMUN:CGN
|
96.6B EUR | 0.5 | 20.1 | 10.3 | 13.8 | |
US |
Cigna Corp
NYSE:CI
|
103.7B USD | 0.5 | 20.1 | 10.3 | 13.8 | ||
US |
CVS Health Corp
NYSE:CVS
|
86.5B USD | 0.2 | 10.4 | 8.9 | 8.9 | ||
DE |
Fresenius Medical Care AG
XMUN:FME
|
22.2B EUR | 1.1 | 44.4 | 10.4 | 24.6 | ||
US |
Laboratory Corporation of America Holdings
NYSE:LH
|
16.7B USD | 1.4 | 38.6 | 11.8 | 17.7 | ||
DE |
F
|
Fresenius SE & Co KGaA
XETRA:FRE
|
15.3B EUR | 0.7 | -25.8 | 9.9 | 22.2 | |
US |
Quest Diagnostics Inc
NYSE:DGX
|
14.9B USD | 1.6 | 17.7 | 10.6 | 14.2 | ||
DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11B EUR | 0.6 | 22 | 6.7 | 15.9 | |
US |
DaVita Inc
NYSE:DVA
|
11.9B USD | 1 | 17.1 | 8.4 | 12.3 | ||
US |
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | 4.4 | -18.6 | -23.3 | -21.5 |